Business Context and Reporting Period
This Form 8-K Current Report, filed on April 28, 2025, covers events occurring on April 22, 2025, and effective May 2, 2025, for Spero Therapeutics, Inc. The filing details significant changes in executive leadership and board composition, specifically the appointment of a new President and Chief Executive Officer (CEO) and the departure of the former CEO.
Key Financial Metrics and Compensation
The filing does not report operational financial metrics such as revenue, profit, cash flow, or debt levels. Instead, it discloses specific compensation and severance figures associated with executive transitions:
- New CEO Compensation (Esther Rajavelu): Annual base salary of $620,000; target annual cash bonus of 50% of base salary ($310,000); grant of 185,000 restricted stock units (RSUs) vesting over four years.
- Former CEO Severance (Satyavrat Shukla): Salary continuation of $615,825 (12 months); cash bonus of $307,913; unpaid retention bonus of $452,813; notice pay for a 30-day period; and COBRA health insurance premium coverage until May 31, 2026.
Material Changes Versus Prior Period
The primary material change is the leadership transition effective May 2, 2025:
- Appointment: Esther Rajavelu transitions from Interim President and CEO to permanent President and CEO. She retains her roles as Chief Financial Officer, Treasurer, and Chief Business Officer and is nominated for election to the Board of Directors.
- Departure: Satyavrat Shukla separates from the Company as President, CEO, and Board member. The resignation is described as mutual and not related to any disagreement regarding operations, policies, or practices.
Outlook, Risks, and Contingencies
The filing outlines specific contingencies regarding executive compensation upon termination:
- Change of Control Provisions: If Ms. Rajavelu is terminated without Cause or resigns for Good Reason within 90 days prior to or one year following a Change of Control, she is entitled to 18 months of base salary, 1.5x the target bonus, and full acceleration of unvested equity.
- Standard Termination: For standard termination without Cause or for Good Reason, Ms. Rajavelu receives 12 months of base salary, a pro-rated bonus, and 12 months of health coverage.
- Equity Treatment: Upon separation, Mr. Shukla's vested and unexercised options remain exercisable for 90 days.
Key Facts for Investor Verification
- Verify the exact effective date of the leadership transition (May 2, 2025) and the immediate impact on corporate governance.
- Confirm the total cash outflow for the former CEO's separation package, which exceeds $1.3 million in immediate and near-term cash obligations.
- Review the upcoming Form 10-Q for the quarter ending March 31, 2025, which will contain the full text of the Amended Employment Agreement and Separation Agreement as exhibits.
- Monitor the 2025 annual meeting of stockholders for the election of Esther Rajavelu to the Board of Directors.